Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Vorolanib Monotherapy As Third-line or Later Treatment for Advanced Non-small Cell Lung Cancer Patients: a Single-arm, Prospective, Open-label Phase II Clinical Study

NCT06728852 is registered in ClinicalTrials.gov with Li-kun Chen as lead sponsor.

NCT NCT06728852
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06728852 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Vorolanib Monotherapy As Third-line or Later Treatment for Advanced Non-small Cell Lung Cancer Patients: a Single-arm, Prospective, Open-label Phase II Clinical Study
Lead sponsor
Li-kun Chen
Phase
Phase 2
Overall status
Recruiting
Start date
December 1, 2024
Completion date
December 1, 2026
Enrollment
32 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced non-small cell lung cancer (nsclc), angiogenesis inhibition in oncology, recurrent or metastatic lung cancer, third-line and beyond therapy